CN1555415A - 合成的hcv包膜蛋白和它们用于接种的应用 - Google Patents

合成的hcv包膜蛋白和它们用于接种的应用 Download PDF

Info

Publication number
CN1555415A
CN1555415A CNA028180828A CN02818082A CN1555415A CN 1555415 A CN1555415 A CN 1555415A CN A028180828 A CNA028180828 A CN A028180828A CN 02818082 A CN02818082 A CN 02818082A CN 1555415 A CN1555415 A CN 1555415A
Authority
CN
China
Prior art keywords
hcv
protein
composition
thr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028180828A
Other languages
English (en)
Chinese (zh)
Inventor
ά
刘易斯·内维尔
阿里·曹贝尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XTL Biopharmaceuticals Ltd
Original Assignee
XTL Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XTL Biopharmaceuticals Ltd filed Critical XTL Biopharmaceuticals Ltd
Publication of CN1555415A publication Critical patent/CN1555415A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA028180828A 2001-09-13 2002-09-09 合成的hcv包膜蛋白和它们用于接种的应用 Pending CN1555415A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14544001A IL145440A0 (en) 2001-09-13 2001-09-13 Synthetic hcv envelope proteins and their use for vaccination
IL145440 2001-09-13

Publications (1)

Publication Number Publication Date
CN1555415A true CN1555415A (zh) 2004-12-15

Family

ID=11075784

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028180828A Pending CN1555415A (zh) 2001-09-13 2002-09-09 合成的hcv包膜蛋白和它们用于接种的应用

Country Status (8)

Country Link
US (1) US20050069865A1 (cg-RX-API-DMAC7.html)
EP (1) EP1427827A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005510211A (cg-RX-API-DMAC7.html)
KR (1) KR20040041612A (cg-RX-API-DMAC7.html)
CN (1) CN1555415A (cg-RX-API-DMAC7.html)
CA (1) CA2460509A1 (cg-RX-API-DMAC7.html)
IL (1) IL145440A0 (cg-RX-API-DMAC7.html)
WO (1) WO2003022880A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563362B (zh) * 2006-08-25 2015-02-11 麦克法兰布奈特医疗研究与公共健康研究所有限公司 重组hcv e2糖蛋白
CN105330730A (zh) * 2014-07-29 2016-02-17 中国科学院上海巴斯德研究所 一种丙型肝炎病毒重组蛋白的制备及其应用
CN116768983A (zh) * 2020-10-28 2023-09-19 王立良 一种用于慢性乙型肝炎预防和/或治疗的蛋白、编码基因、重组腺相关病毒及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
US9758794B2 (en) * 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2726914A1 (en) * 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections
WO2012162137A1 (en) * 2011-05-20 2012-11-29 Emory University Hepatitis c virus particles, vaccines, compositions and methods related thereto

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849987A (en) * 1992-06-02 1998-12-15 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563362B (zh) * 2006-08-25 2015-02-11 麦克法兰布奈特医疗研究与公共健康研究所有限公司 重组hcv e2糖蛋白
CN105330730A (zh) * 2014-07-29 2016-02-17 中国科学院上海巴斯德研究所 一种丙型肝炎病毒重组蛋白的制备及其应用
CN116768983A (zh) * 2020-10-28 2023-09-19 王立良 一种用于慢性乙型肝炎预防和/或治疗的蛋白、编码基因、重组腺相关病毒及其应用

Also Published As

Publication number Publication date
WO2003022880A3 (en) 2003-10-09
EP1427827A2 (en) 2004-06-16
KR20040041612A (ko) 2004-05-17
US20050069865A1 (en) 2005-03-31
CA2460509A1 (en) 2003-03-20
IL145440A0 (en) 2002-06-30
JP2005510211A (ja) 2005-04-21
WO2003022880A2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
CN1207306C (zh) 用于预防和治疗hiv感染和免疫疾病的肽组合物
CN1068335A (zh) C型肝炎诊断制剂和疫苗
CN100339395C (zh) 戊型肝炎病毒单克隆抗体及其用途
CN1125877C (zh) 庚型肝炎病毒及其分子克隆
CN1659440A (zh) 同时检测传染性微生物的抗原及抗体的方法
CN1345775A (zh) 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
CN1622828A (zh) 用于诊断和治疗用途的纯化的丙型肝炎病毒外被蛋白
CN1063507A (zh) 肠道传染性非a/非b型肝炎病毒因子及其特有的抗原决定簇
CN1249781A (zh) 登革病毒的前m/m蛋白的表位、合成肽
CN1227610A (zh) 抗cd4和趋化因子受体结构域复合物的抗体及其抵抗hiv感染的应用
CN1130566C (zh) 用于同时检测乙型肝炎病毒和丙型肝炎病毒的试剂盒和方法
CN1768078A (zh) 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
CN87106696A (zh) 蛋白质及其制备方法,adn的顺序,抗体及其用途,痘病病毒,被转化或感染的细胞用于预防血吸虫病的药剂组合物,以及作为谷胱甘肽-s-转移酶活性的显示剂的用途
CN1255540C (zh) 一株疫苗诱导的乙型肝炎病毒株及其应用
CN1056382C (zh) 改进的丙型肝炎诊断试剂
CN1195774C (zh) 新的hev抗原肽及方法
CN1977045A (zh) Sars核酸,蛋白质,疫苗以及它们的用途
CN101039955A (zh) 与sars冠状病毒刺突蛋白相关的核酸、多肽、表达方法和免疫原性组合物
CN1547588A (zh) 用于诊断和治疗用途的纯化的丙型肝炎病毒外被蛋白
KR20040041612A (ko) 합성 씨형 간염 바이러스 엔벨롭 단백질 및 그 백신 용도
CN1612942A (zh) 病毒衣壳组装中间产物
CN1433430A (zh) 肝炎病毒岗哨病毒ⅰ(svi)
CN1305898C (zh) 丙型肝炎病毒被膜蛋白hvr1模拟多肽、其编码基因及用途
CN1125826C (zh) 新型戊型肝炎病毒基因序列及其应用
CN1616485A (zh) Sars冠状病毒结构蛋白orf3及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication